Infectious Encephalitis: Clinical Trials

44 trials for Infectious Encephalitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 44 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 344Completed 39, Unknown 3, Not yet recruiting 1, Recruiting 1
Phase 24Completed 3, Not yet recruiting 1

Follow Infectious Encephalitis: new trials by email Literature Review of Infectious Encephalitis trials Research Report on Infectious Encephalitis

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dexamethasone in Tick-borne Encephalitis
Dexametasone, Saline (0.9% NaCl) - Tick-Borne Encephalitis
Phase 3RecruitingUniversity Medical Centre Ljubljana2002024-05-032026-05-13
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection - Progressive Multifocal Leukoencephalopathy
Phase 2 / Phase 3Not yet recruitingAssistance Publique - Hôpitaux de Paris332024-04-012024-02-26
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
TBE vaccine 0.5 mL, TBE vaccine 0.25 mL - Tick-Borne Encephalitis
Phase 3CompletedPfizer1652021-01-182023-11-22
Dexamethasone in Herpes Simplex Virus Encephalitis
Dexamethasone - HSV Encephalitis
Phase 3UnknownUniversity Hospital, Grenoble302018-11-012020-09-04
Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam
JEVAX, JECEVAX - Japanese Encephalitis
Phase 3CompletedNational Institute of Hygiene and Epidemiology, Vietnam6552017-09-302018-09-17
Purified Inactivated Japanese Encephalitis Vaccine
Japanese Encephalitis Vaccine produced by IMBCAMS, Japanese Encephalitis Vaccine produced by Liaoning Chenda - Japanese Encephalitis Virus Disease
Phase 3UnknownChinese Academy of Medical Sciences10502015-09-012022-03-09
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) - Japanese Encephalitis
Phase 3CompletedSanofi Pasteur, a Sanofi Company2502015-06-012022-03-28
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2502015-01-012021-02-10
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) - Encephalitis
Phase 3CompletedJiangsu Province Centers for Disease Control and Prevention9002014-10-012016-09-01
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
IMOJEV - Japanese Encephalitis
Phase 3CompletedSanofi Pasteur, a Sanofi Company1192013-07-112022-03-28
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Rabies, Japanese Encephalitis, Placebo - Rabies, Japanese Encephalitis
Phase 3CompletedNovartis Vaccines6612012-08-012014-12-08
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis5522011-11-012014-03-11
Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
FSME-immune - Tick-borne Encephalitis
Phase 2 / Phase 3CompletedSormland County Council, Sweden2002011-09-012015-11-18
Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
Live attenuated Japanese encephalitis chimeric virus vaccine, Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) - Japanese Encephalitis, Japanese Encephalitis Virus Disease
Phase 3CompletedSanofi Pasteur, a Sanofi Company2742011-07-012014-04-25
Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
IXIARO - Japanese Encephalitis
Phase 3CompletedValneva Austria GmbH3002010-12-012014-12-19
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
Blood draw, IC51 has given in the parent study IC51-322 - Japanese Encephalitis
Phase 3CompletedValneva Austria GmbH232010-10-012020-03-18
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella
Phase 3CompletedSanofi Pasteur, a Sanofi Company4542010-08-252022-03-28
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus - Japanese Encephalitis, Measles
Phase 3CompletedSanofi Pasteur, a Sanofi Company5422010-08-012014-08-15
Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea
JE vaccine - Japanese Encephalitis
Phase 3CompletedBoryung Pharmaceutical Co., Ltd2052010-08-012014-01-30
Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
JEVAC - Encephalitis, Japanese B
Phase 3CompletedMahidol University1522010-05-012014-11-18

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Encephalitis, Japanese (32)  ·  Encephalitis, Tick-Borne (10)  ·  Encephalitis (4)  ·  Rabies (2)  ·  Chickenpox (1)  ·  Dengue (1)  ·  Encephalitis, Herpes Simplex (1)  ·  Hepatitis A (1)  ·  Leukoencephalopathy, Progressive Multifocal (1)  ·  Malaria (1)  ·  Measles (1)  ·  Meningitis, Meningococcal (1)  ·  Meningococcal Infections (1)  ·  Mumps (1)  ·  Rubella (1)

Broader conditions

Brain Diseases (44)  ·  Central Nervous System Diseases (44)  ·  Central Nervous System Infections (44)  ·  Central Nervous System Viral Diseases (44)  ·  Encephalitis, Viral (44)  ·  Infections (44)  ·  Nervous System Diseases (44)  ·  Neuroinflammatory Diseases (44)  ·  Virus Diseases (44)  ·  Arbovirus Infections (42)  ·  Encephalitis, Arbovirus (42)  ·  Flaviviridae Infections (42)  ·  Flavivirus Infections (42)  ·  RNA Virus Infections (42)

Interventions

Japanese Encephalitis Vaccines (5)  ·  Vaccines (4)  ·  Blood Specimen Collection (2)  ·  Hepatitis A Vaccines (2)  ·  SA-14-14-2 vaccine (2)  ·  Chickenpox Vaccine (1)  ·  ChimeriVax (1)  ·  Dexamethasone (1)  ·  Immunization, Secondary (1)  ·  Injections (1)  ·  Measles Vaccine (1)  ·  MenACWY-CRM vaccine (1)  ·  Rabies Vaccines (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)

Sponsors

Valneva Austria GmbH (11)  ·  Sanofi Pasteur, a Sanofi Company (8)  ·  Pfizer (7)  ·  PATH (2)  ·  Sanofi (2)  ·  Sormland County Council, Sweden (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Boryung Pharmaceutical Co., Ltd (1)  ·  Chinese Academy of Medical Sciences (1)  ·  Helsinki University Central Hospital (1)  ·  Jiangsu Province Centers for Disease Control and Prevention (1)  ·  London School of Hygiene and Tropical Medicine (1)  ·  Mahidol University (1)  ·  National Institute of Hygiene and Epidemiology, Vietnam (1)  ·  Novartis (1)

Countries

Austria (7)  ·  Germany (7)  ·  Philippines (6)  ·  Poland (4)  ·  Thailand (4)  ·  Australia (3)  ·  South Korea (3)  ·  United States (3)  ·  China (2)  ·  Czechia (2)  ·  Finland (2)  ·  France (2)  ·  Sweden (2)  ·  Vietnam (2)  ·  Japan (1)

Top investigators

Astrid Kaltenboeck, Ph.D. (3)  ·  Jerzy Brzostek, MD (2)  ·  Jerzy Dziduch, MD (2)  ·  Jerzy Romaszko, MD (2)  ·  Krzysztof Sladek, MD (2)  ·  Marian Patrzalek, MD (2)  ·  Salvacion Gatchalian, MD (2)  ·  Susanne Eder (2)  ·  Susanne Eder, Mag. (2)  ·  Andrea Ayad, Dr. (1)  ·  Anu Kantele, MD PhD (1)

Results publications

PMID 20934459, PMID 18394765, PMID 21288804, PMID 22696017, PMID 22777096, PMID 23967083, PMID 24656175, PMID 24717964, PMID 24873986, PMID 25308927, PMID 25483480, PMID 25567119, PMID 26005163, PMID 26994987, PMID 29081368, PMID 29325161, PMID 32156630, PMID 35101266, PMID 38614954

NIH funding

2008 (1), 2023 (1)